Statements of Operations-Additional Information (Tables)

12 Months Ended

Jun. 30, 2022

Statements of Operations-Additional Information

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type

For the Year Ended June 30	2022		2021		2020
Animal Health
MFAs and other	$	361,538	$	330,017	$	322,300
Nutritional specialties		157,196		142,760		129,264
Vaccines		88,321		72,939		75,340
Total Animal Health	$	607,055	$	545,716	$	526,904
Mineral Nutrition		259,512		220,560		214,412
Performance Products		75,694		67,074		59,038
Total	$	942,261	$	833,350	$	800,354

Net Sales by Region

For the Year Ended June 30	2022		2021		2020
United States	$	561,803	$	494,889	$	471,938
Latin America and Canada		191,047		166,325		158,939
Europe, Middle East and Africa		122,480		114,131		112,179
Asia Pacific		66,931		58,005		57,298
Total	$	942,261	$	833,350	$	800,354

Schedule of interest expense, net

For the Year Ended June 30	2022		2021		2020
Interest expense, net
Term loan	$	8,962	$	7,951	$	7,751
Revolving credit facility		2,956		3,649		5,317
Amortization of debt issuance costs		590		833		882
Refinancing expense		—		1,020		—
Other		183		265		663
Interest expense		12,691		13,718		14,613
Interest income		(816)		(838)		(1,757)
	$	11,875	$	12,880	$	12,856

Schedule of depreciation and amortization

For the Year Ended June 30	2022		2021		2020
Depreciation and amortization
Depreciation of property, plant and equipment	$	23,781	$	23,165	$	23,250
Amortization of intangible assets		8,924		8,715		8,869
Amortization of other assets		—		5		222
	$	32,705	$	31,885	$	32,341

Schedule of amortization of intangible assets

For the Year Ended June 30
2023	$	9,614
2024		9,375
2025		7,769
2026		6,805
2027		6,556
Thereafter		23,742
Total	$	63,861

Schedule of research and development expense

For the Year Ended June 30	2022		2021		2020
Research and development expense	$	20,832	$	17,759	$	13,738